Supplement Makers Push FDA to Expand Approved Ingredients Beyond Traditional Diet Sources

Products like BPC-157, an injectable peptide widely used in anti-aging clinics and fitness circles, are already showing up in capsule and gummy form online. Under current law, FDA attorneys say those sales violate federal statute because the compounds are not clearly derived from food. That enforcement gap sat at the center of a public FDA meeting this spring, where supplement industry groups formally pressed the agency to rewrite the foundational rules governing what qualifies as a dietary ingredient.

The Natural Products Association, along with other industry lobbying organizations, argued in letters and public testimony that the FDA's long-standing requirement, which generally limits dietary supplement ingredients to substances found in the human diet, is outdated and anticompetitive. Robert Durkin, a former FDA supplements official who now consults for the industry, told meeting attendees that "the hope of the meeting is that FDA is willing to open up its interpretation of what constitutes a dietary ingredient" to allow substances never traditionally used in food.

Industry representatives framed the push as a consumer-protection measure, arguing that a narrow reading of the law drives buyers toward unregulated gray-market products and raises costs for companies trying to operate inside regulated channels. But medical and public-health groups countered that the argument inverts the logic of drug safety: many peptides have limited clinical safety data, carry immunogenic risks, and are currently manufactured and marketed without adequate quality controls.

Kyle Diamantas, the FDA's senior food official, acknowledged the pressure to modernize. "The industry has grown tremendously over the last 30 years yet the regulatory framework has largely stayed the same," he said at the meeting. Diamantas added that the agency wants to reduce unnecessary red tape but must weigh that goal against protecting public health, a tension the meeting did not resolve.

The practical stakes of any redefinition are significant. If FDA loosens the dietary ingredient standard, manufacturers could begin labeling a broader array of novel compounds as supplements, triggering a lighter regulatory regime: no requirement for pre-market approval, reduced adverse-event reporting obligations, and no mandate to conduct clinical trials before products reach shelves. Consumer advocates and doctors at the meeting urged the agency to establish explicit permitted-ingredient lists, strengthened labeling requirements, and formal safety-evaluation pathways before any expansion takes effect.

The debate is unfolding under a politically charged backdrop. HHS Secretary Robert F. Kennedy Jr. has signaled a more permissive posture toward supplements and alternative health products since taking office, a shift that has already prompted concern from public-health researchers. Kennedy's influence over FDA's regulatory posture adds urgency to what might otherwise be a technical definitional dispute, because a loosened framework under a permissive administration could set precedents that outlast any single political moment.

Policymakers and physicians watching the proceeding noted that the fight over peptides is not isolated: it arrives amid surging public interest in weight-loss drugs, longevity treatments, and injectable wellness interventions. Whether FDA draws a sharper line between drugs and supplements, or allows industry to blur it, will determine how many of those products reach consumers with what level of scrutiny attached.